{"matching_results": 28564, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1666, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1354}, {"key": "negative", "matching_results": 299}, {"key": "neutral", "matching_results": 13}]}]}, {"key": "freelancer.com.co", "matching_results": 719, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 670}, {"key": "negative", "matching_results": 47}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "watchlistnews.com", "matching_results": 581, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 427}, {"key": "negative", "matching_results": 154}]}]}, {"key": "tickerreport.com", "matching_results": 562, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 481}, {"key": "negative", "matching_results": 81}]}]}, {"key": "dailypolitical.com", "matching_results": 530, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 421}, {"key": "negative", "matching_results": 109}]}]}, {"key": "theolympiareport.com", "matching_results": 497, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 346}, {"key": "negative", "matching_results": 151}]}]}, {"key": "wkrb13.com", "matching_results": 489, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 386}, {"key": "negative", "matching_results": 103}]}]}, {"key": "zolmax.com", "matching_results": 480, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 379}, {"key": "negative", "matching_results": 101}]}]}, {"key": "prnewswire.com", "matching_results": 452, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 414}, {"key": "negative", "matching_results": 38}]}]}, {"key": "news.morningstar.com", "matching_results": 378, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "negative", "matching_results": 192}, {"key": "positive", "matching_results": 181}, {"key": "neutral", "matching_results": 5}]}]}]}], "results": [{"id": "Uk36c9D49YFYG8-tSQ3Q5dz5HFmcE9IFUgZ56rNmkpggSD23a6BDMkYhKnNwvptF", "result_metadata": {"score": 37.43719}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.881087, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.779571, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944017, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858826, "count": 1}]}, "crawl_date": "2018-11-27T09:24:33Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45374336-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T08:55:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.414576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.807281, "label": "/real estate/buying and selling homes"}, {"score": 0.764456, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.755369, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.848095, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.690763, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.645889, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637949, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.632136, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.630513, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612733, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597277, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.740284, "label": "negative"}, "relevance": 0.593487, "count": 2}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576877, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573881, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.567425, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567354, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.566652, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564249, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563963, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561202, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555905, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.554905, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.5512, "count": 5}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.551043, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.548087, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547646, "count": 2}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.544582, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54326, "count": 1}, {"text": "disclosure Dealing Disclosure26/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540502, "count": 1}, {"text": "Bank", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.538759, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.537861, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536018, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532656, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.528078, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526358, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525723, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525613, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523425, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.522381, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517507, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512816, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512633, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.512321, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511421, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.509187, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.499031, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.497197, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496333, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492573, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48565, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.481823, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.478283, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.470896, "count": 1}]}, "extracted_metadata": {"sha1": "d6b214c75689c41650e94603c07356ba964419e7", "filename": "1543310673433.zip-ae3063c2095839c840fe4a7f49847639.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "q-97aI_cw694K7IcsCRWcZC5_nNfeBZkhDgeR1iSLuHL52ppyaTCNSWt6GCDqInI", "result_metadata": {"score": 36.905254}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.896398, "label": "/finance/investing"}, {"score": 0.896398, "label": "/finance/investing/beginning investing"}, {"score": 0.88517, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995975, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.840093, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.191512, "count": 1}]}, "crawl_date": "2018-11-27T13:34:14Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45377959-hbk-investments-lp-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T13:37:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.988692, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.910266, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.83781, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.749921, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.679365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.679365, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418973, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945303, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.805651, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Hedge fund", "relevance": 0.778056, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Investment", "relevance": 0.727384, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Collective investment scheme", "relevance": 0.687831, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Security", "relevance": 0.670192, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Mutual fund", "relevance": 0.64546, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643202, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Name", "relevance": 0.641726, "dbpedia_resource": "http://dbpedia.org/resource/Name"}], "categories": [{"score": 0.810546, "label": "/finance/investing/funds"}, {"score": 0.803437, "label": "/real estate/buying and selling homes"}, {"score": 0.79765, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [302, 307], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [280, 283], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.828157, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.697913, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.647805, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.636224, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624045, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616033, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.74856, "label": "negative"}, "relevance": 0.595763, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.589863, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589451, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.582135, "count": 2}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575932, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.57215, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571749, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569448, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565923, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.565396, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.561557, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560195, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.558148, "count": 5}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555216, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555034, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554596, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554313, "count": 2}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.549906, "count": 1}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.543737, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.542798, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542153, "count": 1}, {"text": "behalf", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537989, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.537055, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535274, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532248, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531943, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531839, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529103, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525772, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524157, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522823, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522782, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.521793, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51644, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515011, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512486, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.511867, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.508848, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504983, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.503069, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.500146, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496035, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48919, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.485661, "count": 1}]}, "extracted_metadata": {"sha1": "79f9a875c3000cef822002ae74483d79187abb0d", "filename": "1543325654993.zip-09e94d06ddc2dea390259bd8bc7128fc.xml", "file_type": "json"}, "title": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "Qfzu12EKRoGj4zm9b3dfEOjA_Ab8ahQ4ftdxy9ZnKfpe9GX-D878FeNVwIxPd_Bh", "result_metadata": {"score": 36.34395}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.928193, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "London Stock Exchange", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "Stock exchange", "relevance": 0.767321, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "London", "relevance": 0.5355, "dbpedia_resource": "http://dbpedia.org/resource/London"}, {"text": "Stock", "relevance": 0.518143, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}], "categories": [{"score": 0.861029, "label": "/finance/investing"}, {"score": 0.861029, "label": "/finance/investing/beginning investing"}, {"score": 0.832083, "label": "/finance/investing/day trading"}], "relations": [], "keywords": [{"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999883, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741197, "count": 1}, {"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542745, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.166515, "count": 1}]}, "crawl_date": "2018-11-27T13:58:52Z", "url": "http://www.4-traders.com/LONDON-STOCK-EXCHANGE-4005918/news/London-Stock-Exchange-HBK-Investments-LP-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27668034/", "host": "4-traders.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T00:00:00+01:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.614424, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.554792, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.532546, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.525182, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jonathan Brown", "relevance": 0.508787, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501383, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49134, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.473142, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.473142, "type": "Quantity"}], "sentiment": {"document": {"score": 0.570084, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd (d)", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "state the latest practicable date prior to the disclosure 26 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "latest practicable date"}, {"text": "disclosure"}, {"text": "addition"}, {"text": "state"}]}, "sentence": " For an opening position disclosure, state the latest practicable date prior to the disclosure 26 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " 1.201 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "1.201 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " 1.201 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "the Code", "keywords": [{"text": "Code"}]}, "sentence": " Date of disclosure: 27 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.957224, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.517898, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Futures contract", "relevance": 0.50988, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Strike price", "relevance": 0.499479, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.490819, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.448664, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.419005, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.409351, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.403402, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Security", "relevance": 0.384182, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Derivative", "relevance": 0.376662, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Unit type", "relevance": 0.37247, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Stock", "relevance": 0.370859, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.361642, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Short", "relevance": 0.35803, "dbpedia_resource": "http://dbpedia.org/resource/Short_(finance)"}, {"text": "Derivatives", "relevance": 0.348958, "dbpedia_resource": "http://dbpedia.org/resource/Derivatives"}, {"text": "Security", "relevance": 0.345676, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.343438, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.339372, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Moneyness", "relevance": 0.338731, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Long", "relevance": 0.337732, "dbpedia_resource": "http://dbpedia.org/resource/Long_(finance)"}], "categories": [{"score": 0.940065, "label": "/real estate/buying and selling homes"}, {"score": 0.870608, "label": "/finance/financial news"}, {"score": 0.805131, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [311, 316], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [289, 292], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary (ISIN: JP3463 4) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 100 0.000 0 0.000 (2) Cash-settled derivatives: 9,425,600 1.201 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:  TOTAL: 100 0.000 9,425,600 1.201 All interests and all short positions should be disclosed.", "score": 0.531913, "arguments": [{"text": "Number % Number %", "location": [1682, 1699], "entities": [{"type": "Organization", "text": "Number % Number %", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Interests Short", "location": [1656, 1671], "entities": [{"type": "Organization", "text": "Interests Short", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Ordinary Total Return Swap Increasing a short position 400,000 USD 37.9342 Ordinary Total Return Swap Increasing a short position 371,200 USD 38.0657 (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.726237, "arguments": [{"text": "i", "location": [3345, 3346], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3348, 3355], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3945, 3950], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3955, 3959], "entities": [{"type": "Organization", "text": "Price per unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4319, 4325], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4336, 4343], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 27 November 2018 Contact name: Jonathan Brown Telephone number*: +44 (0)20 7659 1906 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [5226, 5232], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5240, 5244], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5307, 5331], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5299, 5304], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5586, 5610], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5578, 5583], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5642, 5647], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5661, 5688], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.790591, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.688582, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.654952, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.640987, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.637483, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.60567, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.600766, "count": 3}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588661, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.586133, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.564124, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561887, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556921, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5525, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.547977, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.543565, "count": 1}, {"text": "options", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.541457, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.541378, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.541378, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.540693, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.539068, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.538514, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536078, "count": 1}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.535688, "count": 2}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.535485, "count": 4}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.535454, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.535125, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534279, "count": 1}, {"text": "unit", "sentiment": {"score": 0.568074, "label": "positive"}, "relevance": 0.534006, "count": 4}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.533694, "count": 2}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.532642, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.531499, "count": 1}, {"text": "Jonathan Brown Telephone number", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.531129, "count": 1}, {"text": "unit Ordinary Total Return Swap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530869, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.530138, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.529604, "count": 1}, {"text": "November", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.529404, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528405, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.528008, "count": 6}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527874, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.527749, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527708, "count": 2}, {"text": "Code", "sentiment": {"score": -0.536992, "mixed": "1", "label": "negative"}, "relevance": 0.527439, "count": 3}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527233, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.527233, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525388, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.52486, "count": 3}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.524812, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52473, "count": 1}, {"text": "Contact name", "sentiment": {"score": -0.857024, "label": "negative"}, "relevance": 0.524293, "count": 1}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.524069, "count": 1}]}, "extracted_metadata": {"sha1": "676e5790fcbd2b8ad3a78a632cb04e848dbbbfc5", "filename": "1543327132324.zip-6aebf0645f9d14af0be2e8456aabf3a2.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "London Stock Exchange : HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "BwdES4L8lfgc4zki2YuAM1iupp13VWa1qLjouJwfk_xTx6lrHD-dujZLV6dqKU19", "result_metadata": {"score": 36.108852}, "author": "Wayne Duggan", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.598297, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Health care", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Health", "relevance": 0.615825, "dbpedia_resource": "http://dbpedia.org/resource/Health"}], "categories": [{"score": 0.950372, "label": "/finance/investing"}, {"score": 0.950372, "label": "/finance/investing/beginning investing"}, {"score": 0.782827, "label": "/health and fitness/men's health"}], "relations": [{"type": "memberOf", "sentence": "9 Policy Catalysts For Health Care Investors To Watch Before Year's End", "score": 0.460097, "arguments": [{"text": "Investors", "location": [35, 44], "entities": [{"type": "Person", "text": "Investors"}]}, {"text": "Policy Catalysts For Health Care", "location": [2, 34], "entities": [{"type": "Organization", "text": "Policy Catalysts For Health Care"}]}]}], "keywords": [{"text": "Policy Catalysts", "sentiment": {"score": 0.598297, "label": "positive"}, "relevance": 0.986268, "count": 1}, {"text": "Health Care Investors", "sentiment": {"score": 0.598297, "label": "positive"}, "relevance": 0.394144, "count": 1}, {"text": "Year's End", "sentiment": {"score": 0.598297, "label": "positive"}, "relevance": 0.020953, "count": 1}]}, "crawl_date": "2018-11-26T20:31:29Z", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/18/11/12745249/9-policy-catalysts-for-health-care-investors-to-watch-b", "host": "benzinga.com", "text": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co.,", "main_image_url": "https://cdn2.benzinga.com/files/imagecache/bz2_opengraph_meta_image_400x300/images/story/2012/health-846780_1280.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-25T09:35:00Z", "enriched_text": {"entities": [{"count": 24, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.836594, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.312728, "label": "negative"}, "text": "Andrea Harris", "relevance": 0.370077, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.33335, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "RHHBY", "relevance": 0.298036, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.358838, "label": "positive"}, "text": "Cardinal Health Inc", "relevance": 0.260486, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "UnitedHealth Group Inc", "relevance": 0.25111, "type": "Company", "disambiguation": {"subtype": [], "name": "UnitedHealth Group", "dbpedia_resource": "http://dbpedia.org/resource/UnitedHealth_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "October Viking Therapeutics", "relevance": 0.237691, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "House of Representatives", "relevance": 0.236255, "type": "Organization", "disambiguation": {"subtype": ["GovernmentalBody", "Legislature"], "name": "United States House of Representatives", "dbpedia_resource": "http://dbpedia.org/resource/United_States_House_of_Representatives"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anthem Inc", "relevance": 0.22369, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aetna Inc", "relevance": 0.21478, "type": "Company", "disambiguation": {"subtype": [], "name": "Aetna", "dbpedia_resource": "http://dbpedia.org/resource/Aetna"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Goldman Sachs", "relevance": 0.211784, "type": "Company", "disambiguation": {"subtype": ["CompanyShareholder"], "name": "Goldman Sachs", "dbpedia_resource": "http://dbpedia.org/resource/Goldman_Sachs"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "UNH", "relevance": 0.205244, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of New Haven", "dbpedia_resource": "http://dbpedia.org/resource/University_of_New_Haven"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc", "relevance": 0.205032, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.203548, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.199324, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Procter & Gamble Co", "relevance": 0.198626, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Webster Financial Corporation", "relevance": 0.197085, "type": "Company", "disambiguation": {"subtype": [], "name": "Webster Bank", "dbpedia_resource": "http://dbpedia.org/resource/Webster_Bank"}}, {"count": 1, "sentiment": {"score": -0.5132, "label": "negative"}, "text": "DoJ", "relevance": 0.195066, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Healthequity Inc", "relevance": 0.192724, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd", "relevance": 0.192556, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364821, "label": "positive"}, "text": "Humana Inc", "relevance": 0.189701, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bernstein", "relevance": 0.189681, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany", "CompanyShareholder"], "name": "AllianceBernstein", "dbpedia_resource": "http://dbpedia.org/resource/AllianceBernstein"}}, {"count": 1, "sentiment": {"score": -0.5132, "label": "negative"}, "text": "Cryptomania", "relevance": 0.189646, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.189246, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Holdings", "relevance": 0.187339, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.236866, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.187169, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corporation", "relevance": 0.187016, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CIGNA Corporation", "relevance": 0.185434, "type": "Company", "disambiguation": {"subtype": [], "name": "Cigna", "dbpedia_resource": "http://dbpedia.org/resource/Cigna"}}, {"count": 1, "sentiment": {"score": -0.500132, "label": "negative"}, "text": "Congress", "relevance": 0.185384, "type": "Organization", "disambiguation": {"subtype": ["Dedicator", "GovernmentalBody", "Legislature", "NaturalOrCulturalPreservationAgency"], "name": "United States Congress", "dbpedia_resource": "http://dbpedia.org/resource/United_States_Congress"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.18431, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Co", "relevance": 0.182175, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Stryker Corporation", "relevance": 0.181035, "type": "Company", "disambiguation": {"subtype": [], "name": "Stryker Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Stryker_Corporation"}}, {"count": 1, "sentiment": {"score": -0.380808, "label": "negative"}, "text": "Sanofi SA", "relevance": 0.180804, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.271868, "label": "positive"}, "text": "Cadillac", "relevance": 0.180427, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corporation", "relevance": 0.177599, "type": "Company", "disambiguation": {"subtype": [], "name": "Boston Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Becton Dickinson", "relevance": 0.17715, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cliff", "relevance": 0.170731, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences, Inc.", "relevance": 0.168202, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.293198, "label": "positive"}, "text": "Amgen, Inc.", "relevance": 0.166377, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Edwards Lifesciences Corp", "relevance": 0.155838, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.155023, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medtronic PLC", "relevance": 0.152571, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SNY", "relevance": 0.151665, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan NV", "relevance": 0.151021, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Centene Corp", "relevance": 0.146557, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.40978, "label": "negative"}, "text": "Molina Healthcare, Inc.", "relevance": 0.144402, "type": "Company"}], "sentiment": {"document": {"score": 0.325011, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "What Are The Biggest International Stocks Traded Over-The-Counter", "keywords": [{"text": "Biggest International Stocks"}]}, "sentence": "Related RHHBY What Are The Biggest International Stocks Traded Over-The-Counter?", "object": {"text": "RHHBY", "keywords": [{"text": "RHHBY"}]}, "action": {"verb": {"text": "Related", "tense": "past"}, "text": "Related", "normalized": "Related"}}, {"subject": {"text": "The Biggest International Stocks", "keywords": [{"text": "Biggest International Stocks"}]}, "sentence": "Related RHHBY What Are The Biggest International Stocks Traded Over-The-Counter?", "object": {"text": "Over-The-Counter"}, "action": {"verb": {"text": "Traded", "tense": "past"}, "text": "Traded", "normalized": "Traded"}}, {"subject": {"text": "The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics", "keywords": [{"text": "Actively Traded OTCQX"}, {"text": "OTCQB Stocks"}, {"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "October Viking Therapeutics"}]}, "sentence": " The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics Won't Live Up To The Hype (Seeking Alpha) Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives .", "object": {"text": "To The Hype", "keywords": [{"text": "Hype"}]}, "action": {"verb": {"text": "Live", "tense": "future", "negated": true}, "text": "Live", "normalized": "Live"}}, {"subject": {"text": "Health care investors", "keywords": [{"text": "Health care investors"}]}, "sentence": " The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics Won't Live Up To The Hype (Seeking Alpha) Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives .", "object": {"text": "both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives", "keywords": [{"text": "final stretch"}, {"text": "GOP-controlled House"}, {"text": "Representatives"}], "entities": [{"type": "Organization", "text": "House of Representatives", "disambiguation": {"subtype": ["GovernmentalBody", "Legislature"], "name": "United States House of Representatives", "dbpedia_resource": "http://dbpedia.org/resource/United_States_House_of_Representatives"}}]}, "action": {"verb": {"text": "enter", "tense": "present"}, "text": "are entering", "normalized": "be enter"}}, {"subject": {"text": "Height Capital Markets analyst Andrea Harris", "keywords": [{"text": "analyst Andrea Harris"}, {"text": "Height"}], "entities": [{"type": "JobTitle", "text": "analyst"}, {"type": "Person", "text": "Andrea Harris"}]}, "sentence": " Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December in a recent note.", "object": {"text": "nine potential health care catalysts", "keywords": [{"text": "health care catalysts"}]}, "action": {"verb": {"text": "survey", "tense": "past"}, "text": "surveyed", "normalized": "survey"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December in a recent note.", "action": {"verb": {"text": "watch", "tense": "future"}, "text": "should be watching", "normalized": "should be watch"}}, {"subject": {"text": "We"}, "sentence": " Two Imminent Measures \u201cWe believe that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year,\u201d Harris said.", "object": {"text": "that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year", "keywords": [{"text": "Over-the-Counter Monograph Safety"}, {"text": "All-Hazards Preparedness Act"}, {"text": "best chance"}, {"text": "Reform Act"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "Harris", "keywords": [{"text": "Harris"}], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, "sentence": " Two Imminent Measures \u201cWe believe that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year,\u201d Harris said.", "object": {"text": "Two Imminent Measures \u201cWe believe that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year", "keywords": [{"text": "Over-the-Counter Monograph Safety"}, {"text": "All-Hazards Preparedness Act"}, {"text": "Imminent Measures"}, {"text": "best chance"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Other key pieces of health care legislation", "keywords": [{"text": "health care legislation"}, {"text": "key pieces"}]}, "sentence": " Other key pieces of health care legislation might still make it through in 2019 as well, the analyst said.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "make", "normalized": "make"}}, {"subject": {"text": "the analyst", "keywords": [{"text": "analyst"}], "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " Other key pieces of health care legislation might still make it through in 2019 as well, the analyst said.", "object": {"text": "Other key pieces of health care legislation might still make it through in 2019 as well", "keywords": [{"text": "health care legislation"}, {"text": "key pieces"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe further believe that legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix, and CREATES Act) are possible to enact in 2018, but Congress will more likely address these issues in 2019.\"", "object": {"text": "that legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix, and CREATES Act) are possible to enact in 2018", "keywords": [{"text": "TrOOP cliff fix"}, {"text": "health insurer fee"}, {"text": "drug pricing legislation"}, {"text": "health care taxes"}], "entities": [{"type": "Company", "text": "Cadillac"}, {"type": "Person", "text": "cliff"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA", "keywords": [{"text": "health insurer fee"}, {"text": "drug pricing legislation"}, {"text": "health care taxes"}, {"text": "Cadillac tax"}], "entities": [{"type": "Company", "text": "Cadillac"}]}, "sentence": " \u201cWe further believe that legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix, and CREATES Act) are possible to enact in 2018, but Congress will more likely address these issues in 2019.\"", "object": {"text": "Act", "keywords": [{"text": "Act"}]}, "action": {"verb": {"text": "CREATES", "tense": "present"}, "text": "CREATES", "normalized": "CREATES"}}, {"subject": {"text": "legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix", "keywords": [{"text": "health insurer fee"}, {"text": "drug pricing legislation"}, {"text": "BBA fix"}, {"text": "health care taxes"}], "entities": [{"type": "Company", "text": "Cadillac"}, {"type": "Person", "text": "cliff"}]}, "sentence": " \u201cWe further believe that legislation to address health care taxes (device tax, Cadillac tax and the health insurer fee) and drug pricing legislation (BBA fix, TrOOP cliff fix, and CREATES Act) are possible to enact in 2018, but Congress will more likely address these issues in 2019.\"", "object": {"text": "possible"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Other pieces of legislation", "keywords": [{"text": "legislation"}, {"text": "pieces"}]}, "sentence": " Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said:", "object": {"text": "additional companies", "keywords": [{"text": "additional companies"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "could impact", "normalized": "could impact"}}, {"subject": {"text": "Harris", "keywords": [{"text": "Harris"}], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, "sentence": " Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said:", "object": {"text": "Other Impacted Stocks Other pieces of legislation could impact additional companies", "keywords": [{"text": "Impacted Stocks"}, {"text": "additional companies"}, {"text": "legislation"}, {"text": "pieces"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The DoJ", "keywords": [{"text": "DoJ"}], "entities": [{"type": "Organization", "text": "DoJ"}]}, "sentence": " With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania", "object": {"text": "Investigating Last Year's Cryptomania", "entities": [{"type": "Location", "text": "Cryptomania", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "Is", "tense": "present"}, "text": "Is", "normalized": "Is"}}, {"subject": {"text": "The DoJ", "keywords": [{"text": "DoJ"}], "entities": [{"type": "Organization", "text": "DoJ"}]}, "sentence": " With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania", "object": {"text": "'s Cryptomania", "keywords": [{"text": "Cryptomania"}], "entities": [{"type": "Location", "text": "Cryptomania", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "Investigating", "tense": "present"}, "text": "Is Investigating", "normalized": "Is Investigating"}}], "concepts": [{"text": "Health care", "relevance": 0.989072, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.965944, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "UnitedHealth Group", "relevance": 0.779365, "dbpedia_resource": "http://dbpedia.org/resource/UnitedHealth_Group"}, {"text": "Health insurance", "relevance": 0.747557, "dbpedia_resource": "http://dbpedia.org/resource/Health_insurance"}, {"text": "Becton Dickinson", "relevance": 0.729376, "dbpedia_resource": "http://dbpedia.org/resource/Becton_Dickinson"}], "categories": [{"score": 0.724297, "label": "/finance/investing/stocks"}, {"score": 0.692872, "label": "/finance/investing/options"}, {"score": 0.660301, "label": "/health and fitness/drugs"}], "relations": [{"type": "partOf", "sentence": "The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics Won't Live Up To The Hype (Seeking Alpha) Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives .", "score": 0.610421, "arguments": [{"text": "Health", "location": [205, 211], "entities": [{"type": "Organization", "text": "Healthequity Inc"}]}, {"text": "Alpha", "location": [198, 203], "entities": [{"type": "Organization", "text": "Viking Therapeutics Won't Live Up To The Hype"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.916962, "arguments": [{"text": "Takeda Pharmaceutical Co Ltd", "location": [750, 778], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TKPYY", "location": [785, 790], "entities": [{"type": "Ticker", "text": "TKPYY"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.910233, "arguments": [{"text": "Merck & Co., Inc.", "location": [794, 811], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MRK", "location": [819, 822], "entities": [{"type": "Ticker", "text": "MRK"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.936357, "arguments": [{"text": "Cardinal Health Inc", "location": [826, 845], "entities": [{"type": "Organization", "text": "Cardinal Health Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CAH", "location": [853, 856], "entities": [{"type": "Ticker", "text": "CAH"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.907453, "arguments": [{"text": "Johnson & Johnson", "location": [894, 911], "entities": [{"type": "Organization", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "JNJ", "location": [919, 922], "entities": [{"type": "Ticker", "text": "JNJ"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.611406, "arguments": [{"text": "Anthem Inc", "location": [1717, 1727], "entities": [{"type": "Organization", "text": "Anthem Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ANTM", "location": [1735, 1739], "entities": [{"type": "Ticker", "text": "ANTM"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.488733, "arguments": [{"text": "Aetna Inc", "location": [1742, 1751], "entities": [{"type": "Organization", "text": "Aetna Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AET", "location": [1759, 1762], "entities": [{"type": "Ticker", "text": "AET"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.393636, "arguments": [{"text": "CIGNA Corporation", "location": [1765, 1782], "entities": [{"type": "Organization", "text": "CIGNA Corporation"}]}, {"text": "CI", "location": [1790, 1792], "entities": [{"type": "Ticker", "text": "CI"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.484693, "arguments": [{"text": "Humana Inc", "location": [1795, 1805], "entities": [{"type": "Organization", "text": "Humana Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "HUM", "location": [1813, 1816], "entities": [{"type": "Ticker", "text": "HUM"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.39514, "arguments": [{"text": "Centene Corp", "location": [1819, 1831], "entities": [{"type": "Organization", "text": "Centene Corp"}]}, {"text": "CNC", "location": [1839, 1842], "entities": [{"type": "Ticker", "text": "CNC"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.581361, "arguments": [{"text": "Inc.", "location": [1864, 1868], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MOH", "location": [1876, 1879], "entities": [{"type": "Ticker", "text": "MOH"}]}]}, {"type": "employedBy", "sentence": "The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics Won't Live Up To The Hype (Seeking Alpha) Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives .", "score": 0.530012, "arguments": [{"text": "investors", "location": [217, 226], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Alpha", "location": [198, 203], "entities": [{"type": "Organization", "text": "Viking Therapeutics Won't Live Up To The Hype"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.656068, "arguments": [{"text": "UnitedHealth Group Inc", "location": [1882, 1904], "entities": [{"type": "Organization", "text": "UnitedHealth Group Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "UNH", "location": [1912, 1915], "entities": [{"type": "Ticker", "text": "UNH"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.390364, "arguments": [{"text": "WellCare Health Plans, Inc.", "location": [1918, 1945], "entities": [{"type": "Organization", "text": "WellCare Health Plans, Inc."}]}, {"text": "WCG", "location": [1953, 1956], "entities": [{"type": "Ticker", "text": "WCG"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.601064, "arguments": [{"text": "Co", "location": [1980, 1982], "entities": [{"type": "Organization", "text": "Procter & Gamble Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BDX", "location": [1990, 1993], "entities": [{"type": "Ticker", "text": "BDX"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.442055, "arguments": [{"text": "Boston Scientific Corporation", "location": [1996, 2025], "entities": [{"type": "Organization", "text": "Boston Scientific Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BSX", "location": [2033, 2036], "entities": [{"type": "Ticker", "text": "BSX"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.378004, "arguments": [{"text": "Edwards Lifesciences Corp", "location": [2039, 2064], "entities": [{"type": "Organization", "text": "Edwards Lifesciences Corp"}]}, {"text": "EW", "location": [2072, 2074], "entities": [{"type": "Ticker", "text": "EW"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.486908, "arguments": [{"text": "Medtronic PLC", "location": [2077, 2090], "entities": [{"type": "Organization", "text": "Medtronic PLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MDT", "location": [2098, 2101], "entities": [{"type": "Ticker", "text": "MDT"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.497646, "arguments": [{"text": "Stryker Corporation", "location": [2104, 2123], "entities": [{"type": "Organization", "text": "Stryker Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SYK", "location": [2131, 2134], "entities": [{"type": "Ticker", "text": "SYK"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.466532, "arguments": [{"text": "Mylan NV", "location": [2137, 2145], "entities": [{"type": "Organization", "text": "Mylan NV", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MYL", "location": [2155, 2158], "entities": [{"type": "Ticker", "text": "MYL"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.570146, "arguments": [{"text": "Teva Pharmaceutical Industries Ltd ADR", "location": [2161, 2199], "entities": [{"type": "Organization", "text": "Teva Pharmaceutical Industries Ltd ADR", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TEVA", "location": [2207, 2211], "entities": [{"type": "Ticker", "text": "TEVA"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.816234, "arguments": [{"text": "Celgene Corporation", "location": [2214, 2233], "entities": [{"type": "Organization", "text": "Celgene Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CELG", "location": [2243, 2247], "entities": [{"type": "Ticker", "text": "CELG"}]}]}, {"type": "employedBy", "sentence": "The 10 Most Actively Traded OTCQX And OTCQB Stocks In October Viking Therapeutics Won't Live Up To The Hype (Seeking Alpha) Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives .", "score": 0.478483, "arguments": [{"text": "investors", "location": [217, 226], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Health", "location": [205, 211], "entities": [{"type": "Organization", "text": "Healthequity Inc"}]}]}, {"type": "hasAttribute", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.818201, "arguments": [{"text": "Gilead Sciences, Inc.", "location": [2250, 2271], "entities": [{"type": "Organization", "text": "Gilead Sciences, Inc."}]}, {"text": "GILD", "location": [2281, 2285], "entities": [{"type": "Ticker", "text": "GILD"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.875677, "arguments": [{"text": "Amgen, Inc.", "location": [2288, 2299], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AMGN", "location": [2309, 2313], "entities": [{"type": "Ticker", "text": "AMGN"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.818947, "arguments": [{"text": "AbbVie Inc", "location": [2316, 2326], "entities": [{"type": "Organization", "text": "AbbVie Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ABBV", "location": [2334, 2338], "entities": [{"type": "Ticker", "text": "ABBV"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.824916, "arguments": [{"text": "Pfizer Inc.", "location": [2341, 2352], "entities": [{"type": "Organization", "text": "Merck & Co., Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "PFE", "location": [2360, 2363], "entities": [{"type": "Ticker", "text": "PFE"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.709453, "arguments": [{"text": "Healthequity Inc", "location": [2366, 2382], "entities": [{"type": "Organization", "text": "Healthequity Inc"}]}, {"text": "HQY", "location": [2392, 2395], "entities": [{"type": "Ticker", "text": "HQY"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.88771, "arguments": [{"text": "UnitedHealth Group Inc", "location": [2398, 2420], "entities": [{"type": "Organization", "text": "UnitedHealth Group Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "UNH", "location": [2428, 2431], "entities": [{"type": "Ticker", "text": "UNH"}]}]}, {"type": "hasAttribute", "sentence": "Amgen, Inc. (NASDAQ: AMGN ) AbbVie Inc (NYSE: ABBV ) Pfizer Inc. (NYSE: PFE ) Healthequity Inc (NASDAQ: HQY ) UnitedHealth Group Inc (NYSE: UNH ) Webster Financial Corporation (NYSE: WBS ) The Height Capital chart below indicates which legislative measures the firm believes are likely to pass and which specific stocks could be impacted: Related Links: The Health Care Stocks With A Lot Riding On The Midterm Elections With Tether In Focus, The DoJ Is Investigating Last Year's Cryptomania Latest Ratings for RHHBY Date Firm Action From To Nov 2018 Goldman Sachs Downgrades Conviction Buy Buy May 2018 Credit Suisse Downgrades Neutral Underperform May 2018 Bernstein Downgrades Outperform Market Perform View More Analyst Ratings for RHHBY View the Latest Analyst Ratings", "score": 0.777759, "arguments": [{"text": "Webster Financial Corporation", "location": [2434, 2463], "entities": [{"type": "Organization", "text": "Webster Financial Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "WBS", "location": [2471, 2474], "entities": [{"type": "Ticker", "text": "WBS"}]}]}, {"type": "locatedAt", "sentence": "Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December in a recent note.", "score": 0.371479, "arguments": [{"text": "analyst", "location": [361, 368], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "Capital Markets", "location": [345, 360], "entities": [{"type": "GeopoliticalEntity", "text": "Capital Markets"}]}]}, {"type": "agentOf", "sentence": "Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December in a recent note.", "score": 0.99835, "arguments": [{"text": "Andrea Harris", "location": [369, 382], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "surveyed", "location": [383, 391], "entities": [{"type": "EventCommunication", "text": "surveyed"}]}]}, {"type": "agentOf", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.996056, "arguments": [{"text": "Harris", "location": [586, 592], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "said", "location": [593, 597], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Two Imminent Measures \"We believe that a reauthorization of the Pandemic and All-Hazards Preparedness Act (S. 2852) and the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R. 5333) stand the best chance of passage this year,\" Harris said.", "score": 0.997278, "arguments": [{"text": "Harris", "location": [1214, 1220], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "said", "location": [1221, 1225], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Other key pieces of health care legislation might still make it through in 2019 as well, the analyst said.", "score": 0.967626, "arguments": [{"text": "analyst", "location": [1320, 1327], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "said", "location": [1328, 1332], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\" Other Impacted Stocks Other pieces of legislation could impact additional companies, Harris said: Anthem Inc (NYSE: ANTM ) Aetna Inc (NYSE: AET ) CIGNA Corporation (NYSE: CI ) Humana Inc (NYSE: HUM ) Centene Corp (NYSE: CNC ) Molina Healthcare, Inc. (NYSE: MOH ) UnitedHealth Group Inc (NYSE: UNH ) WellCare Health Plans, Inc. (NYSE: WCG ) Becton Dickinson and Co (NYSE: BDX ) Boston Scientific Corporation (NYSE: BSX ) Edwards Lifesciences Corp (NYSE: EW ) Medtronic PLC (NYSE: MDT ) Stryker Corporation (NYSE: SYK ) Mylan NV (NASDAQ: MYL ) Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) Celgene Corporation (NASDAQ: CELG ) Gilead Sciences, Inc. (NASDAQ: GILD )", "score": 0.822645, "arguments": [{"text": "Harris", "location": [1704, 1710], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "said", "location": [1711, 1715], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOfMany", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.774378, "arguments": [{"text": "Harris", "location": [586, 592], "entities": [{"type": "Person", "text": "Andrea Harris"}]}, {"text": "them", "location": [617, 621], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.930116, "arguments": [{"text": "Roche Holdings AG Basel ADR Common Stock", "location": [670, 710], "entities": [{"type": "Organization", "text": "Roche Holdings AG Basel ADR Common Stock", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "RHHBY", "location": [717, 722], "entities": [{"type": "Ticker", "text": "RHHBY"}]}]}, {"type": "hasAttribute", "sentence": "Of the nine potential legislative catalysts ahead in the next month, Harris said she expects two of them to pass: measures that would financially impact Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ), Sanofi SA (NYSE: SNY ), Takeda Pharmaceutical Co Ltd (OTC: TKPYY ), Merck & Co., Inc. (NYSE: MRK ), Cardinal Health Inc (NYSE: CAH ), GlaxoSmithKline plc (NYSE: GSK ), Johnson & Johnson (NYSE: JNJ ), and Procter & Gamble Co (NYSE: PG ).", "score": 0.919815, "arguments": [{"text": "Sanofi SA", "location": [726, 735], "entities": [{"type": "Organization", "text": "Sanofi SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SNY", "location": [743, 746], "entities": [{"type": "Ticker", "text": "SNY"}]}]}], "keywords": [{"text": "NYSE", "sentiment": {"score": -0.442571, "mixed": "1", "label": "negative"}, "relevance": 0.738705, "count": 24}, {"text": "Cardinal Health Inc", "sentiment": {"score": 0.318567, "label": "positive"}, "relevance": 0.6487, "count": 1}, {"text": "Health care investors", "sentiment": {"score": -0.817102, "label": "negative"}, "relevance": 0.623318, "count": 1}, {"text": "CIGNA Corporation", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.596794, "count": 1}, {"text": "Biggest International Stocks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594158, "count": 1}, {"text": "Related RHHBY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570632, "count": 1}, {"text": "potential health care catalysts", "sentiment": {"score": 0.684035, "label": "positive"}, "relevance": 0.560257, "count": 1}, {"text": "Anthem Inc", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.559194, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": -0.597141, "mixed": "1", "label": "negative"}, "relevance": 0.556555, "count": 5}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555401, "count": 1}, {"text": "key pieces of health care legislation", "sentiment": {"score": 0.730439, "label": "positive"}, "relevance": 0.550085, "count": 1}, {"text": "UnitedHealth Group Inc", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.541682, "count": 2}, {"text": "Boston Scientific Corporation", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.540427, "count": 1}, {"text": "health care taxes", "sentiment": {"score": 0.854414, "label": "positive"}, "relevance": 0.539585, "count": 1}, {"text": "measures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538611, "count": 1}, {"text": "Becton Dickinson", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.537323, "count": 1}, {"text": "Teva Pharmaceutical Industries Ltd ADR", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.534406, "count": 1}, {"text": "OTCQB Stocks", "sentiment": {"score": -0.817102, "label": "negative"}, "relevance": 0.531866, "count": 1}, {"text": "Stocks", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.530912, "count": 1}, {"text": "legislation", "sentiment": {"score": 0.854414, "label": "positive"}, "relevance": 0.530859, "count": 2}, {"text": "Aetna Inc", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.530516, "count": 1}, {"text": "Inc.", "sentiment": {"score": -0.654305, "mixed": "1", "label": "negative"}, "relevance": 0.530319, "count": 5}, {"text": "final stretch", "sentiment": {"score": -0.817102, "label": "negative"}, "relevance": 0.529738, "count": 1}, {"text": "Harris", "sentiment": {"score": -0.572797, "mixed": "1", "label": "negative"}, "relevance": 0.526607, "count": 3}, {"text": "firm", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.526416, "count": 1}, {"text": "UNH", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.526055, "count": 2}, {"text": "RHHBY Date Firm Action", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.525169, "count": 1}, {"text": "OTC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525088, "count": 2}, {"text": "Tether", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.524827, "count": 1}, {"text": "TEVA", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.524682, "count": 1}, {"text": "analyst", "sentiment": {"score": 0.730439, "label": "positive"}, "relevance": 0.524247, "count": 1}, {"text": "Webster Financial Corporation", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.52192, "count": 1}, {"text": "Hazards Preparedness Act", "sentiment": {"score": -0.831273, "label": "negative"}, "relevance": 0.520997, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.318567, "label": "positive"}, "relevance": 0.520334, "count": 2}, {"text": "Centene Corp", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.519737, "count": 1}, {"text": "potential legislative catalysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519498, "count": 1}, {"text": "Height Capital chart", "sentiment": {"score": 0.906502, "label": "positive"}, "relevance": 0.518519, "count": 1}, {"text": "Humana Inc", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.516998, "count": 1}, {"text": "GlaxoSmithKline plc", "sentiment": {"score": 0.318567, "label": "positive"}, "relevance": 0.516833, "count": 1}, {"text": "additional companies", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.516342, "count": 1}, {"text": "Stryker Corporation", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.515847, "count": 1}, {"text": "Imminent Measures", "sentiment": {"score": -0.831273, "label": "negative"}, "relevance": 0.514939, "count": 1}, {"text": "MDT", "sentiment": {"score": -0.9153, "label": "negative"}, "relevance": 0.514082, "count": 1}, {"text": "AET", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.514026, "count": 1}, {"text": "CI", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.513815, "count": 1}, {"text": "HUM", "sentiment": {"score": 0.265507, "label": "positive"}, "relevance": 0.513626, "count": 1}, {"text": "Amgen", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513588, "count": 1}, {"text": "Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513519, "count": 1}, {"text": "investors", "sentiment": {"score": 0.684035, "label": "positive"}, "relevance": 0.51339, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51328, "count": 1}]}, "extracted_metadata": {"sha1": "570d6a2cb5644fc16fa700f844973e7602df8e67", "filename": "1543264289773.zip-d932e2d3dcc66ae96ef3c13858203dd8.xml", "file_type": "json"}, "external_links": ["https://seekingalpha.com/article/4222613-viking-therapeutics-live-hype?source=partner_benzinga"], "title": "9 Policy Catalysts For Health Care Investors To Watch Before Year's End", "forum_title": "The Best of Benzinga"}, {"id": "dw3fGhUdo2UVn0v83tc8U9vU0Klzr5DkKPs9JonYB6vYNlYzgx7VUoW7tEZxHM-2", "result_metadata": {"score": 35.361626}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "score": 0.617534, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955242, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399959, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.065678, "count": 1}]}, "crawl_date": "2018-11-26T21:23:32Z", "url": "https://globenewswire.com/news-release/2018/11/26/1656601/0/en/Anchiano-Therapeutics-Announces-Appointment-of-Dr-David-Kerstein-as-New-Chief-Medical-Officer.html", "host": "globenewswire.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "main_image_url": "http://globenewswire.com/Attachment/LogoDisplay/560940?filename=560940.jpg&size=1", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T13:30:00Z", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Kerstein", "relevance": 0.881949, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.413553, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics Anchiano Therapeutics", "relevance": 0.38198, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.468284, "label": "negative"}, "text": "Anchiano Therapeutics", "relevance": 0.377586, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.334913, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.27286, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Medical Officer", "relevance": 0.267888, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.235259, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano", "relevance": 0.223574, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": 0.433481, "label": "positive"}, "text": "President and Chief Executive Officer", "relevance": 0.213832, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.468284, "label": "negative"}, "text": "President and Chief Executive Officerinfo", "relevance": 0.208544, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.202823, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.200302, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.193048, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": -0.241901, "label": "negative"}, "text": "bladder cancer.", "relevance": 0.191495, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.333462, "label": "positive"}, "text": "urinary bladder", "relevance": 0.189807, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.184339, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.183023, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CAMBRIDGE", "relevance": 0.182114, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.179528, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.172583, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.286249, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.172319, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.167281, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.158319, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.15624, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.147076, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambridge", "relevance": 0.146095, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.140153, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Officerinfo@anchiano.com", "relevance": 0.140153, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.393281, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the discovery and development of novel therapies to treat cancer,", "keywords": [{"text": "novel therapies"}, {"text": "discovery"}, {"text": "development"}, {"text": "cancer"}]}, "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "the appointment of David Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "appointment"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the Company", "keywords": [{"text": "Company"}]}, "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}], "entities": [{"type": "JobTitle", "text": "Chief Medical Officer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "Anchiano\u2019s", "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "We look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "About David Kerstein, M.D. Dr. Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "M.D."}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "David Kerstein"}, {"type": "Person", "text": "David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "initial New Drug"}, {"text": "clinical development program"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "About Anchiano Therapeutics Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}, "sentence": " About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "BC-819"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Statements This press release", "keywords": [{"text": "press release"}, {"text": "Statements"}], "entities": []}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\u201d that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.967987, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.939614, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.718585, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.692606, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.64484, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.644121, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.621285, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.532826, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Urinary bladder", "relevance": 0.468357, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Clinical research", "relevance": 0.461059, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Chief executive officer", "relevance": 0.456435, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Executive officer", "relevance": 0.438631, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Therapy", "relevance": 0.418832, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Latin honors", "relevance": 0.382281, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.379537, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Drug design", "relevance": 0.372015, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Pharmaceutical drug", "relevance": 0.360286, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Oncology", "relevance": 0.334804, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Pre-clinical development", "relevance": 0.334313, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Chief executives", "relevance": 0.333559, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Urology", "relevance": 0.330622, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "Cancer staging", "relevance": 0.325873, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "New chemical entity", "relevance": 0.325132, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Corporate governance", "relevance": 0.32422, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Bladder cancer", "relevance": 0.322724, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}, {"text": "Physician", "relevance": 0.318049, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}, {"text": "Doctor of Medicine", "relevance": 0.317649, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}], "categories": [{"score": 0.978114, "label": "/science/medicine/oncology"}, {"score": 0.926229, "label": "/health and fitness/disease/cancer"}, {"score": 0.813495, "label": "/health and fitness/therapy"}], "relations": [{"type": "locatedAt", "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.706652, "arguments": [{"text": "Anchiano Therapeutics CAMBRIDGE", "location": [37, 68], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics CAMBRIDGE", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Mass.", "location": [70, 75], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "employedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.252169, "arguments": [{"text": "Kerstein", "location": [947, 955], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Anchiano Therapeutics", "location": [962, 983], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1181, 1183], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1192, 1203], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1332, 1376], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1380, 1407], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1409, 1414], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1380, 1407], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.683487, "arguments": [{"text": "he", "location": [1415, 1417], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1409, 1414], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [1816, 1843], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [1847, 1855], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [1926, 1944], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [1909, 1925], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [1953, 1957], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [1949, 1952], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2188, 2195], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2199, 2208], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2199, 2208], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}, {"text": "MA", "location": [2210, 2212], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "hasAttribute", "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.886958, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [111, 137], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}, {"text": "ANCN", "location": [145, 149], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2218, 2227], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2229, 2235], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2273, 2282], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2241, 2248], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: President and Chief Executive Officerinfo@anchiano.com", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3522, 3534], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3509, 3512], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}]}, {"type": "timeOf", "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.956804, "arguments": [{"text": "today", "location": [272, 277], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [278, 287], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.525427, "arguments": [{"text": "David Kerstein", "location": [307, 321], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [292, 303], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}, {"type": "managerOf", "sentence": "November 26, 2018 08:30 ET | Source: Anchiano Therapeutics CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.464899, "arguments": [{"text": "Chief Medical Officer", "location": [350, 371], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [336, 343], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [628, 641], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [623, 627], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [657, 680], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [684, 705], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [902, 905], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [897, 901], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [947, 955], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [956, 961], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}], "keywords": [{"text": "Anchiano Therapeutics CAMBRIDGE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.684863, "count": 1}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.659086, "count": 2}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606136, "count": 1}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602835, "count": 2}, {"text": "Company\u2019s new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575043, "count": 1}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575, "count": 1}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.574101, "count": 1}, {"text": "Dr. Kerstein", "sentiment": {"score": 0.637429, "label": "positive"}, "relevance": 0.571575, "count": 4}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.564418, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.561595, "count": 1}, {"text": "statements", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.554688, "count": 4}, {"text": "Statements", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.554688, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.552339, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.552119, "count": 1}, {"text": "advanced product candidate", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.552008, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.550943, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.55058, "count": 1}, {"text": "future events", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.54876, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.54776, "count": 1}, {"text": "press release", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.545924, "count": 1}, {"text": "urinary bladder", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.542624, "count": 1}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542153, "count": 2}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541162, "count": 1}, {"text": "development", "sentiment": {"score": -0.556767, "mixed": "1", "label": "negative"}, "relevance": 0.540324, "count": 3}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.538158, "count": 1}, {"text": "risks", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.537503, "count": 3}, {"text": "David", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.536201, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535255, "count": 1}, {"text": "uncertainties", "sentiment": {"score": 0.570817, "label": "positive"}, "relevance": 0.535156, "count": 3}, {"text": "management\u2019s good faith belief", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.531858, "count": 1}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530326, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.527608, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.845002, "label": "positive"}, "relevance": 0.527539, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527532, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.526579, "count": 1}, {"text": "Anchiano", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.52655, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52486, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.524764, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.522842, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522652, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.520017, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.520003, "count": 1}, {"text": "discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519724, "count": 2}, {"text": "today", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519303, "count": 1}, {"text": "results", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.518893, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518654, "count": 1}, {"text": "holdings", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.518421, "count": 1}, {"text": "Company", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.518275, "count": 1}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518259, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.51779, "count": 1}]}, "extracted_metadata": {"sha1": "2a22ebcffe0da4c7da004af1e6aae39b8a2c0fd9", "filename": "1543267412213.zip-d796de643935febbadcb0193d7251c2c.xml", "file_type": "json"}, "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "forum_title": "GlobeNewswire RSS Feed"}, {"id": "1yPSZSuOmDVzpnnam2QPLT0UlMeFOjHu0R2Ix5SF__YIe3FiWg2dIt7ouyqpsErq", "result_metadata": {"score": 34.550205}, "author": "R\u00e9daction", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "score": 0.617534, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955242, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399959, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.065678, "count": 1}]}, "crawl_date": "2018-11-26T15:43:36Z", "url": "https://www.biotech-finances.com/anchiano-therapeutics-announces-appointment-of-dr-david-kerstein-as-new-chief-medical-officer/", "host": "biotech-finances.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T15:26:00Z", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.926264, "type": "Person"}, {"count": 5, "sentiment": {"score": 0.433481, "label": "positive"}, "text": "Anchiano Therapeutics", "relevance": 0.520295, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.468284, "label": "negative"}, "text": "New Chief Medical Officer Anchiano Therapeutics", "relevance": 0.423025, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Anchiano Therapeutics Anchiano Therapeutics", "relevance": 0.366617, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.335078, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.287144, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.28452, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.233053, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.208868, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano", "relevance": 0.196811, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.196465, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.241901, "label": "negative"}, "text": "President and Chief Executive Officerinfo", "relevance": 0.193674, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.177393, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.169927, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Google", "relevance": 0.164746, "type": "Company", "disambiguation": {"subtype": ["AcademicInstitution", "AwardPresentingOrganization", "OperatingSystemDeveloper", "ProgrammingLanguageDeveloper", "SoftwareDeveloper", "VentureFundedCompany"], "name": "Google", "dbpedia_resource": "http://dbpedia.org/resource/Google"}}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.164743, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bladder cancer.", "relevance": 0.164569, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.333462, "label": "positive"}, "text": "urinary bladder", "relevance": 0.161455, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.157748, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.15715, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CAMBRIDGE", "relevance": 0.155723, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.15357, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.14705, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.286249, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.145323, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.142702, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.135953, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.134822, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.12695, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambridge", "relevance": 0.125568, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.120881, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Officerinfo@anchiano.com", "relevance": 0.120881, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.393281, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the discovery and development of novel therapies to treat cancer,", "keywords": [{"text": "novel therapies"}, {"text": "discovery"}, {"text": "development"}, {"text": "cancer"}]}, "sentence": " Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}, {"text": "David Kerstein"}, {"text": "appointment"}, {"text": "M.D."}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}, {"type": "JobTitle", "text": "New Chief Medical Officer"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the Company", "keywords": [{"text": "Company"}]}, "sentence": " Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}], "entities": [{"type": "JobTitle", "text": "New Chief Medical Officer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "Anchiano\u2019s", "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "We look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "About David Kerstein, M.D. Dr. Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "M.D."}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}, {"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "initial New Drug"}, {"text": "clinical development program"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "About Anchiano Therapeutics Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}, "sentence": " About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "BC-819"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Statements This press release", "keywords": [{"text": "press release"}, {"text": "Statements"}], "entities": []}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\u201d that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.980222, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.95858, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.754461, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.732459, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.663509, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.659827, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.637823, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.530271, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Clinical research", "relevance": 0.488258, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Urinary bladder", "relevance": 0.485462, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Executive officer", "relevance": 0.479111, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Chief executive officer", "relevance": 0.475633, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Therapy", "relevance": 0.440231, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Chief executives", "relevance": 0.419626, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Drug design", "relevance": 0.395629, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Latin honors", "relevance": 0.391713, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.382098, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Corporate governance", "relevance": 0.380752, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Management occupations", "relevance": 0.375157, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Pharmaceutical drug", "relevance": 0.361999, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pre-clinical development", "relevance": 0.349785, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Oncology", "relevance": 0.345869, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Urology", "relevance": 0.340582, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "Business and financial operations occupations", "relevance": 0.337294, "dbpedia_resource": "http://dbpedia.org/resource/Business_and_financial_operations_occupations"}, {"text": "Physician", "relevance": 0.335817, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}, {"text": "Specialty", "relevance": 0.329584, "dbpedia_resource": "http://dbpedia.org/resource/Specialty_(medicine)"}, {"text": "New chemical entity", "relevance": 0.32916, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Doctor of Medicine", "relevance": 0.325386, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}, {"text": "Cancer staging", "relevance": 0.32344, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Bladder cancer", "relevance": 0.320824, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}], "categories": [{"score": 0.975812, "label": "/science/medicine/oncology"}, {"score": 0.919398, "label": "/health and fitness/disease/cancer"}, {"score": 0.800941, "label": "/health and fitness/therapy"}], "relations": [{"type": "managerOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.535486, "arguments": [{"text": "Chief Medical Officer", "location": [97, 118], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [93, 96], "entities": [{"type": "Organization", "text": "New Drug Application", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.670708, "arguments": [{"text": "Chief Medical Officer", "location": [192, 213], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [188, 191], "entities": [{"type": "Organization", "text": "New Drug Application", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [885, 898], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [880, 884], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [914, 937], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [941, 962], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [1159, 1162], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [1154, 1158], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [1204, 1212], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [1213, 1218], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}, {"type": "affectedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.446124, "arguments": [{"text": "Anchiano Therapeutics", "location": [1219, 1240], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}, {"text": "joins", "location": [1213, 1218], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1438, 1440], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1449, 1460], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1589, 1633], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1637, 1664], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1666, 1671], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1637, 1664], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.708832, "arguments": [{"text": "he", "location": [1672, 1674], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1666, 1671], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [2073, 2100], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [2104, 2112], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.478801, "arguments": [{"text": "Anchiano Therapeutics Announces Appointment", "location": [119, 162], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}, {"text": "New", "location": [93, 96], "entities": [{"type": "Organization", "text": "New Drug Application", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [2183, 2201], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [2166, 2182], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [2210, 2214], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [2206, 2209], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2445, 2452], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2456, 2465], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2456, 2465], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}, {"text": "MA", "location": [2467, 2469], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2475, 2484], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2486, 2492], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2530, 2539], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2498, 2505], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: President and Chief Executive Officerinfo@anchiano.com", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3779, 3791], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3766, 3769], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "managerOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.383172, "arguments": [{"text": "Chief Medical Officer", "location": [97, 118], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Anchiano Therapeutics Announces Appointment", "location": [119, 162], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "managerOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.504752, "arguments": [{"text": "Chief Medical Officer", "location": [607, 628], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [593, 600], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "timeOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.8964, "arguments": [{"text": "2018", "location": [226, 230], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "novembre", "location": [217, 225], "entities": [{"type": "EventCommunication", "text": "novembre"}]}]}, {"type": "locatedAt", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.691034, "arguments": [{"text": "UTC CAMBRIDGE", "location": [313, 326], "entities": [{"type": "Organization", "text": "UTC CAMBRIDGE"}]}, {"text": "Mass.", "location": [328, 333], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "hasAttribute", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.497893, "arguments": [{"text": "UTC CAMBRIDGE", "location": [313, 326], "entities": [{"type": "Organization", "text": "UTC CAMBRIDGE"}]}, {"text": "ANCN", "location": [402, 406], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "hasAttribute", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.85526, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [368, 394], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Ltd."}]}, {"text": "ANCN", "location": [402, 406], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "timeOf", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.736303, "arguments": [{"text": "today", "location": [529, 534], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [535, 544], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Accueil / Communiqu\u00e9s / Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer 26 novembre 2018 Communiqu\u00e9s Google + Anchiano Therapeutics \u2014 Monday, November 26th 2018 at 1:30pm UTC CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) \u2014 Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.54459, "arguments": [{"text": "David Kerstein", "location": [564, 578], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [549, 560], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.743612, "count": 3}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667213, "count": 2}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.650615, "count": 2}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585142, "count": 2}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.569533, "count": 1}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.561026, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.557972, "count": 1}, {"text": "statements", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.55316, "count": 4}, {"text": "Statements", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.55316, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.5498, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.549725, "count": 1}, {"text": "advanced product candidate", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.549282, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.547364, "count": 1}, {"text": "future events", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.546107, "count": 1}, {"text": "press release", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.54397, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.54355, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540238, "count": 1}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539116, "count": 1}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53824, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.536815, "count": 1}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.535863, "count": 1}, {"text": "development", "sentiment": {"score": -0.556767, "mixed": "1", "label": "negative"}, "relevance": 0.535581, "count": 3}, {"text": "Company\u2019s new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535573, "count": 1}, {"text": "risks", "sentiment": {"score": 0.337119, "mixed": "1", "label": "positive"}, "relevance": 0.53548, "count": 3}, {"text": "uncertainties", "sentiment": {"score": 0.570817, "label": "positive"}, "relevance": 0.533258, "count": 3}, {"text": "urinary bladder", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.532744, "count": 1}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532395, "count": 2}, {"text": "management\u2019s good faith belief", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.530796, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528983, "count": 1}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527438, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.526494, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.525182, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.525146, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.845002, "label": "positive"}, "relevance": 0.523837, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522735, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.521914, "count": 1}, {"text": "David", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.521761, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521075, "count": 1}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520859, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.519382, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518979, "count": 1}, {"text": "results", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.518093, "count": 1}, {"text": "Company", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.517296, "count": 1}, {"text": "holdings", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517293, "count": 1}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517118, "count": 1}, {"text": "complete R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.516962, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.516704, "count": 1}, {"text": "operations", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.516621, "count": 1}, {"text": "rights", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.516522, "count": 1}, {"text": "respect", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.516447, "count": 1}]}, "extracted_metadata": {"sha1": "32ae484db4198ff1711fe7374c9a95d8e282d1cf", "filename": "1543247016917.zip-861763ae1bb78bf5480dc50e0c07249e.xml", "file_type": "json"}, "external_links": ["https://plusone.google.com/_/+1/confirm?hl=en&url=https://www.biotech-finances.com/?p=69670&name=Anchiano+Therapeutics+Announces+Appointment+of+Dr.+David+Kerstein+as+New+Chief+Medical+Officer", "https://www.globenewswire.com/Tracker?data=q3OUTH-SpvKNYFAGYEXBpG9s_jvGxQuHF1a70sg_rqb6ydEDpoNvVBYbhB0APsvFMzEujK3mQjie069OmmyGYg==", "http://rdf.data-vocabulary.org/#"], "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "forum_title": "EEI-BIOTECHFINANCES"}, {"id": "MhuY6A57G8aHEQFYmTOfgd3aJ1BlmEQDY39IxEKAjlpDekuKAxC8hcgX-Ty6Emi-", "result_metadata": {"score": 32.522636}, "author": "markets.ft.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.935718, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997761, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.832988, "count": 1}]}, "crawl_date": "2018-11-27T10:25:39Z", "url": "https://markets.ft.com/data/announce/detail?dockey=1323-13881671-4RJUOJIOI7LTU4DD4B8R274DIJ", "host": "markets.ft.com", "text": "KEY INFORMATION Full name of person making disclosure: SOCIETE GENERALE SA Name of offeror/offeree in relation to whose relevant securities the disclosure relates: Takeda Pharmaceutical CO LTD 2.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T09:03:00-06:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPY", "relevance": 0.740511, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical CO LTD", "relevance": 0.654162, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Societe Generale SA", "relevance": 0.542856, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.536914, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.501471, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.498173, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SOCIETE GENERALE SA", "relevance": 0.477919, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.59178, "label": "positive"}, "text": "Financial Conduct Authority", "relevance": 0.477213, "type": "Organization", "disambiguation": {"subtype": [], "name": "Financial Conduct Authority", "dbpedia_resource": "http://dbpedia.org/resource/Financial_Conduct_Authority"}}, {"count": 1, "sentiment": {"score": 0.52028, "label": "positive"}, "text": "Olivier Vero", "relevance": 0.469626, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.59178, "label": "positive"}, "text": "United Kingdom", "relevance": 0.455541, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453149, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.436906, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0.59178, "label": "positive"}, "text": "Primary Information Provider", "relevance": 0.413662, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "rns@lseg.com", "relevance": 0.413662, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.413662, "type": "Quantity"}], "sentiment": {"document": {"score": 0.415763, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\"", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit JPY", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "disclosure requirements"}, {"text": "Code"}, {"text": "relation"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "20 7638 0129.The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "person", "keywords": [{"text": "person"}]}, "sentence": " Full name of person making disclosure:", "object": {"text": "disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "It"}, "sentence": " It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives", "keywords": [{"text": "Supplemental Form"}, {"text": "cash-settled derivatives"}, {"text": "Open Positions"}, {"text": "regard"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "This information", "keywords": [{"text": "information"}]}, "sentence": " This information is provided by RNS, the news service of the London Stock Exchange.", "object": {"text": "provided by RNS", "keywords": [{"text": "RNS"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by RNS, the news service of the London Stock Exchange", "keywords": [{"text": "London Stock Exchange"}, {"text": "RNS"}, {"text": "news service"}], "entities": [{"type": "Facility", "text": "London Stock Exchange"}]}, "sentence": " This information is provided by RNS, the news service of the London Stock Exchange.", "object": {"text": "This information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "by the Financial Conduct Authority", "keywords": [{"text": "Financial Conduct Authority"}], "entities": [{"type": "Organization", "text": "Financial Conduct Authority", "disambiguation": {"subtype": [], "name": "Financial Conduct Authority", "dbpedia_resource": "http://dbpedia.org/resource/Financial_Conduct_Authority"}}]}, "sentence": " RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.", "object": {"text": "RNS", "keywords": [{"text": "RNS"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "RNS", "keywords": [{"text": "RNS"}]}, "sentence": " RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.", "object": {"text": "as a Primary Information Provider in the United Kingdom", "keywords": [{"text": "Primary Information Provider"}, {"text": "United Kingdom"}], "entities": [{"type": "JobTitle", "text": "Primary Information Provider"}, {"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}]}, "action": {"verb": {"text": "act", "tense": "future"}, "text": "to act", "normalized": "to act"}}, {"subject": {"text": "Terms and conditions", "keywords": [{"text": "Terms"}, {"text": "conditions"}]}, "sentence": " Terms and conditions relating to the use and distribution of this information may apply.", "object": {"text": "to the use and distribution of this information", "keywords": [{"text": "distribution"}, {"text": "information"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}], "concepts": [{"text": "Option", "relevance": 0.976532, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Nikolai Chernykh", "relevance": 0.800137, "dbpedia_resource": "http://dbpedia.org/resource/Nikolai_Chernykh"}, {"text": "Call option", "relevance": 0.517116, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.514578, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}], "categories": [{"score": 0.955688, "label": "/real estate/buying and selling homes"}, {"score": 0.871091, "label": "/finance/financial news"}, {"score": 0.764239, "label": "/finance/investing/day trading"}], "relations": [{"type": "agentOf", "sentence": "4315 Total Purchases 78,685 Total Sales 91,785 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit JPY  (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit JPY (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit JPY (d) Other dealings (", "score": 0.726237, "arguments": [{"text": "i", "location": [8156, 8157], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [8159, 8166], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [9142, 9148], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [9159, 9166], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 27/11/2018 Contact name: Olivier Vero Telephone number: +44 20 7676 6969 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [10036, 10042], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [10050, 10054], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [10479, 10485], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [10493, 10506], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk SUPPLEMENTAL FORM 8 (OPEN POSITIONS) DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.", "score": 0.766214, "arguments": [{"text": "Market Surveillance Unit", "location": [10117, 10141], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10109, 10114], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [11758, 11782], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [11750, 11755], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [11917, 11922], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [11936, 11963], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "partOf", "sentence": "This information is provided by RNS, the news service of the London Stock Exchange.", "score": 0.733386, "arguments": [{"text": "news service", "location": [12007, 12019], "entities": [{"type": "Organization", "text": "news service", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "London Stock Exchange", "location": [12027, 12048], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "locatedAt", "sentence": "RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.", "score": 0.700444, "arguments": [{"text": "Primary Information Provider", "location": [12113, 12141], "entities": [{"type": "Organization", "text": "Primary Information Provider"}]}, {"text": "United Kingdom", "location": [12149, 12163], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Exercise price", "sentiment": {"score": 0.468857, "label": "positive"}, "relevance": 0.702183, "count": 2}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.657668, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.650916, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.525042, "label": "negative"}, "relevance": 0.632082, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.630032, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613465, "count": 1}, {"text": "RNS Number", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.606129, "count": 1}, {"text": "INFORMATION", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.583795, "count": 1}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.569789, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.565626, "count": 2}, {"text": "Takeover Code", "sentiment": {"score": -0.718851, "label": "negative"}, "relevance": 0.5637, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.440644, "mixed": "1", "label": "positive"}, "relevance": 0.563196, "count": 4}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560667, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558927, "count": 2}, {"text": "Financial Conduct Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558894, "count": 1}, {"text": "Code", "sentiment": {"score": -0.71261, "label": "negative"}, "relevance": 0.548716, "count": 5}, {"text": "short positions", "sentiment": {"score": -0.601197, "label": "negative"}, "relevance": 0.546893, "count": 3}, {"text": "options", "sentiment": {"score": -0.240936, "mixed": "1", "label": "negative"}, "relevance": 0.54109, "count": 4}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.538001, "count": 1}, {"text": "agreements", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.536561, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.53381, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.53381, "count": 1}, {"text": "information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533786, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.442155, "mixed": "1", "label": "negative"}, "relevance": 0.532851, "count": 2}, {"text": "additional class of relevant security", "sentiment": {"score": 0.554182, "mixed": "1", "label": "positive"}, "relevance": 0.532555, "count": 2}, {"text": "RNS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53187, "count": 2}, {"text": "Terms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531144, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530617, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53061, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.53061, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.267522, "mixed": "1", "label": "positive"}, "relevance": 0.529841, "count": 6}, {"text": "voting rights", "sentiment": {"score": 0.645741, "label": "positive"}, "relevance": 0.528157, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.52807, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527824, "count": 1}, {"text": "Regulatory Information Service", "sentiment": {"score": -0.698609, "label": "negative"}, "relevance": 0.527565, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.527516, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.698609, "label": "negative"}, "relevance": 0.526644, "count": 2}, {"text": "Stock", "sentiment": {"score": -0.578169, "label": "negative"}, "relevance": 0.525848, "count": 2}, {"text": "relation", "sentiment": {"score": 0.361947, "mixed": "1", "label": "positive"}, "relevance": 0.525694, "count": 5}, {"text": "INTERESTS", "sentiment": {"score": -0.879363, "label": "negative"}, "relevance": 0.525482, "count": 1}, {"text": "derivatives", "sentiment": {"score": -0.478585, "label": "negative"}, "relevance": 0.525132, "count": 3}, {"text": "agreement", "sentiment": {"score": 0.75988, "label": "positive"}, "relevance": 0.524398, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523883, "count": 1}, {"text": "Supplemental Form", "sentiment": {"score": 0.665929, "label": "positive"}, "relevance": 0.523874, "count": 3}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.523582, "count": 3}, {"text": "Number", "sentiment": {"score": 0.500165, "mixed": "1", "label": "positive"}, "relevance": 0.523326, "count": 2}, {"text": "arrangements", "sentiment": {"score": 0.645741, "label": "positive"}, "relevance": 0.523284, "count": 3}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5222, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522168, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.522095, "count": 1}]}, "extracted_metadata": {"sha1": "9baa119beeb891da9e66f09631357fe1ec94a616", "filename": "1543314339278.zip-30cc45a925752beb4bb52b5fda08e06d.xml", "file_type": "json"}, "external_links": ["http://www.rns.com/"], "title": "Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "Company Announcements \u2013 Latest Company Information \u2013 FT.com"}, {"id": "YEoq09wawgPPlwRGBtqP1c4JVsAubOp7VMldUc-5vjHC__Qs4uBywK4U6ZUTitvX", "result_metadata": {"score": 32.50065}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.858051, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.649159, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975763, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763569, "count": 1}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619358, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602167, "count": 1}]}, "crawl_date": "2018-11-26T23:34:49Z", "url": "https://www.businesswire.com/news/home/20181126005402/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T12:44:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.750177, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.716696, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577763, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.575679, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.553167, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542972, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.529182, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.509096, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.470802, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453686, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,569,600 1.33%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,406,920 1.45%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,351,516 1.55%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,772,173 1.61%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14,304,773 1.80%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,328,036 4.34%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "543,000 0.07%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "989,600 0.12%", "relevance": 0.453686, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453686, "type": "Quantity"}], "sentiment": {"document": {"score": 0.646413, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "relevant securities this form", "keywords": [{"text": "relevant securities"}, {"text": "form"}]}, "sentence": " relevant securities this form relates: (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 12 September 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer?", "object": {"text": "an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 12 September 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer", "keywords": [{"text": "exempt fund manager"}, {"text": "Date position"}, {"text": "discloser making"}, {"text": "disclosures"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " relevant securities this form relates: (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 12 September 2018 (f) In addition to the company in 1(c) above, is the discloser making YES: disclosures in respect of any other party to the offer?", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 34,328,036 4.34% 14,304,773 1.80% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,569,600 1.33"}, {"type": "Quantity", "text": "14,304,773 1.80"}, {"type": "Quantity", "text": "34,328,036 4.34"}, {"type": "Quantity", "text": "989,600 0.12"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,406,920 1.45% 12,772,173 1.61% (2) Cash-settled derivatives: 12,351,516 1.55% 543,000 0.07% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 34,328,036 4.34% 14,304,773 1.80% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "34,328,036 4.34% 14,304,773 1.80% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "14,304,773 1.80"}, {"type": "Quantity", "text": "34,328,036 4.34"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,406,920 1.45% 12,772,173 1.61% (2) Cash-settled derivatives: 12,351,516 1.55% 543,000 0.07% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 34,328,036 4.34% 14,304,773 1.80% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 26 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659970 Time of Receipt (offset from UTC): 20181126T122307+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.986571, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.743914, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.715147, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.641872, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.514384, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Options", "relevance": 0.422313, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Option style", "relevance": 0.415036, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Moneyness", "relevance": 0.381911, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.35883, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.337335, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.334389, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.308106, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.304779, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Barclays", "relevance": 0.300323, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.858539, "label": "/real estate/buying and selling homes"}, {"score": 0.796108, "label": "/finance/financial news"}, {"score": 0.79195, "label": "/finance/investing"}], "relations": [{"type": "basedIn", "sentence": "LONDON- FORM 8.3 Amendment to Purchase PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.629662, "arguments": [{"text": "Amendment", "location": [17, 26], "entities": [{"type": "Organization", "text": "Amendment"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "managerOf", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4528.6397 European 5 Oct 2018 Ordinary NPV Put Options Written 10,000,000 4528.6397 European 5 Oct 2018 3.", "score": 0.325547, "arguments": [{"text": "5", "location": [9185, 9186], "entities": [{"type": "Person", "text": "5"}]}, {"text": "European", "location": [9176, 9184], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659970 Time of Receipt (offset from UTC): 20181126T122307+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [9919, 9922], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [9898, 9905], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "4,561.2307 JPY Ordinary NPV Sale 125,800 4,558.8585 JPY Ordinary NPV Sale 197,000 4,570.5106 JPY Ordinary NPV Sale 256,600 4,563.3382 JPY Ordinary NPV Sale 260,000 4,562.8400 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 7,600 4,599.5400 JPY Ordinary NPV SWAP Short 11,400 4,574.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.500498, "arguments": [{"text": "Cash", "location": [4753, 4757], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [4799, 4813], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "4,561.2307 JPY Ordinary NPV Sale 125,800 4,558.8585 JPY Ordinary NPV Sale 197,000 4,570.5106 JPY Ordinary NPV Sale 256,600 4,563.3382 JPY Ordinary NPV Sale 260,000 4,562.8400 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 7,600 4,599.5400 JPY Ordinary NPV SWAP Short 11,400 4,574.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.657678, "arguments": [{"text": "i", "location": [5053, 5054], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5056, 5063], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [5653, 5658], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [5663, 5667], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6027, 6033], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6044, 6051], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 26 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [6953, 6959], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [6967, 6971], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7399, 7405], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7413, 7426], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7034, 7058], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7026, 7031], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9614, 9638], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9606, 9611], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7193, 7198], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7212, 7239], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9773, 9778], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9792, 9819], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7475, 7481], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7507, 7519], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.446621, "label": "positive"}, "relevance": 0.765678, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.446621, "label": "positive"}, "relevance": 0.649877, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.639209, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.64284, "label": "positive"}, "relevance": 0.626993, "count": 4}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.625581, "count": 18}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.617317, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.607822, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.582476, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.577193, "count": 2}, {"text": "options", "sentiment": {"score": 0.757634, "label": "positive"}, "relevance": 0.574791, "count": 4}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.574705, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.59103, "label": "positive"}, "relevance": 0.574618, "count": 2}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.574479, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.574079, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573692, "count": 1}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.570583, "count": 3}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559491, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.555204, "count": 1}, {"text": "Code", "sentiment": {"score": -0.293675, "mixed": "1", "label": "negative"}, "relevance": 0.554655, "count": 5}, {"text": "INTERESTS", "sentiment": {"score": 0.446621, "label": "positive"}, "relevance": 0.545536, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.545388, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.542447, "count": 10}, {"text": "PERSON", "sentiment": {"score": 0.549416, "label": "positive"}, "relevance": 0.541706, "count": 2}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53918, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.537832, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.535768, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.534551, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.534551, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534346, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532986, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.446621, "label": "positive"}, "relevance": 0.532905, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.532256, "count": 1}, {"text": "positions", "sentiment": {"score": 0.806498, "label": "positive"}, "relevance": 0.53167, "count": 2}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.53095, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530404, "count": 1}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.528704, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.446621, "label": "positive"}, "relevance": 0.528704, "count": 1}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.527184, "count": 5}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.526824, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.526562, "count": 2}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526262, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525926, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.525248, "count": 2}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.525098, "count": 4}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.524207, "count": 2}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.524165, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524123, "count": 3}, {"text": "sale Number of Price", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.524078, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.945515, "label": "positive"}, "relevance": 0.522318, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.522158, "count": 1}]}, "extracted_metadata": {"sha1": "fee675f9581d146658c0e1616577e8941a3d469a", "filename": "1543275289158.zip-a30f90030f3832f7f170f08c6cd3506a.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "forum_title": "All News | Business Wire"}, {"id": "Di-N4UCBEM8eBFPyj-jQK2g8N_v96PYsgZ8Eu9UVf4Ls9hqCilQNWmlIDMMiBkkV", "result_metadata": {"score": 32.277477}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.858051, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.649159, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975763, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763569, "count": 1}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619358, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602167, "count": 1}]}, "crawl_date": "2018-11-26T23:34:49Z", "url": "https://www.businesswire.com/news/home/20181126005409/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "Name of offeror/offeree in relation to whose relevant securities the disclosure relates: TAKEDA PHARMACEUTICAL CO LTD 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T12:53:00-06:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC", "relevance": 0.869617, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.666626, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.540369, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.501911, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.500726, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.494851, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.466885, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.46259, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.441692, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.431246, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.431246, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,400 1.29%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,569,600 1.33%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,989,600 1.38%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,333,711 1.45%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,730,116 1.48%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,050,274 1.52%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,295,274 4.19%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,633,427 4.25%", "relevance": 0.431246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.431246, "type": "Quantity"}], "sentiment": {"document": {"score": 0.56356, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,569,600 1.33% 10,989,600 1.38% (4) TOTAL: 33,633,427 4.25% 33,295,274 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,569,600 1.33"}, {"type": "Quantity", "text": "10,989,600 1.38"}, {"type": "Quantity", "text": "33,295,274 4.19"}, {"type": "Quantity", "text": "33,633,427 4.25"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,333,711 1.45% 12,050,274 1.52% (2) Cash-settled derivatives: 11,730,116 1.48% 10,255,400 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 10,989,600 1.38% (4) TOTAL: 33,633,427 4.25% 33,295,274 4.19% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,633,427 4.25% 33,295,274 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,295,274 4.19"}, {"type": "Quantity", "text": "33,633,427 4.25"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,333,711 1.45% 12,050,274 1.52% (2) Cash-settled derivatives: 11,730,116 1.48% 10,255,400 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 10,989,600 1.38% (4) TOTAL: 33,633,427 4.25% 33,295,274 4.19% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options)", "object": {"text": "unit (c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}, {"text": "unit"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "person", "keywords": [{"text": "person"}]}, "sentence": " Full name of person making disclosure: Barclays PLC.", "object": {"text": "disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659971 Time of Receipt (offset from UTC): 20181126T122527+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.960585, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.718521, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.692232, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.648134, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.498772, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Options", "relevance": 0.419805, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Option style", "relevance": 0.400085, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Moneyness", "relevance": 0.376337, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.343557, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Bond", "relevance": 0.333035, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "United States", "relevance": 0.310127, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Derivative", "relevance": 0.292036, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Unit type", "relevance": 0.291909, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Security", "relevance": 0.284692, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Barclays", "relevance": 0.284334, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Premier League", "relevance": 0.27901, "dbpedia_resource": "http://dbpedia.org/resource/Premier_League"}, {"text": "United Kingdom company law", "relevance": 0.265334, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom_company_law"}], "categories": [{"score": 0.900089, "label": "/real estate/buying and selling homes"}, {"score": 0.824885, "label": "/finance/financial news"}, {"score": 0.797641, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant Purchase/sale Number of Price per unit security securities ADR Purchase 27,506 19.8003 USD ADR Purchase 100,680 19.7966 USD ADR Purchase 149,400 19.8831 USD ADR Sale 27,506 19.8003 USD ADR Sale 100,680 19.7966 USD ADR Sale 149,400 19.8831 USD (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.726237, "arguments": [{"text": "i", "location": [3403, 3404], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3406, 3413], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659971 Time of Receipt (offset from UTC): 20181126T122527+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [8476, 8479], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [8455, 8462], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [4003, 4008], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [4013, 4017], "entities": [{"type": "Organization", "text": "Type e.g. American"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4377, 4383], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4394, 4401], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 26 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "score": 0.756243, "arguments": [{"text": "Rule 8", "location": [5303, 5309], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5317, 5321], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [5828, 5834], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [5842, 5855], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5463, 5487], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5455, 5460], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8171, 8195], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8163, 8168], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5622, 5627], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5641, 5668], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8330, 8335], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8349, 8376], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "employedBy", "sentence": "STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS) Class Product Writing, Number Exercise Type Expiry of description purchasing, of price date relevant selling, securities per unit security varying etc to which option relates Ordinary NPV Call Options Purchased 39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Call Options Purchased 40,000 6182.0000 European 14 Dec 2018 Ordinary NPV Call Options Purchased 48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Call Options Purchased 82,000 5264.7000 European 25 Oct 2018 Ordinary NPV Call Options Written -460,000 6182.0000 European 14 Dec 2018 Ordinary NPV Call Options Written -114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Written -104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Call Options Written -78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Call Options Written -75,900 4286.5200 European 6", "score": 0.344802, "arguments": [{"text": "Dec", "location": [6348, 6351], "entities": [{"type": "Person", "text": "Dec"}]}, {"text": "NPV Call Options Purchased", "location": [6366, 6392], "entities": [{"type": "Organization", "text": "NPV Call Options Purchased"}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.336377, "arguments": [{"text": "6", "location": [7742, 7743], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [7733, 7741], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.436283, "arguments": [{"text": "0", "location": [7816, 7817], "entities": [{"type": "Person", "text": "0"}]}, {"text": "European", "location": [7807, 7815], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.781144, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.665605, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.642651, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.637686, "count": 4}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59731, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.591746, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.582893, "count": 3}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.581791, "count": 2}, {"text": "options", "sentiment": {"score": 0.325244, "mixed": "1", "label": "positive"}, "relevance": 0.581091, "count": 4}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573202, "count": 2}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.968936, "label": "positive"}, "relevance": 0.572297, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.571112, "count": 10}, {"text": "Takeover Code", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.562886, "count": 2}, {"text": "Purchases", "sentiment": {"score": 0.968936, "label": "positive"}, "relevance": 0.562201, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.557152, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552992, "count": 1}, {"text": "Code", "sentiment": {"score": -0.497503, "mixed": "1", "label": "negative"}, "relevance": 0.547237, "count": 5}, {"text": "INTERESTS", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.544306, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.543905, "label": "positive"}, "relevance": 0.542292, "count": 2}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540821, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.539675, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.539125, "count": 2}, {"text": "unit", "sentiment": {"score": 0.347288, "mixed": "1", "label": "positive"}, "relevance": 0.538643, "count": 4}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538076, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537214, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.535672, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.535672, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.534538, "count": 1}, {"text": "Takeover Panel", "sentiment": {"score": -0.760831, "label": "negative"}, "relevance": 0.533216, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.968936, "label": "positive"}, "relevance": 0.532907, "count": 2}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531533, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.433613, "label": "positive"}, "relevance": 0.531533, "count": 1}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.531108, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530513, "count": 1}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.530157, "count": 5}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529954, "count": 1}, {"text": "relevant Purchase", "sentiment": {"score": 0.968936, "label": "positive"}, "relevance": 0.529834, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.529787, "count": 2}, {"text": "sale Number of Price", "sentiment": {"score": 0.968936, "label": "positive"}, "relevance": 0.529707, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52958, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.529114, "count": 1}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.527244, "count": 4}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.526481, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.525885, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525846, "count": 3}, {"text": "disclosure", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.525798, "count": 6}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.525443, "count": 1}, {"text": "offer", "sentiment": {"score": 0.808201, "label": "positive"}, "relevance": 0.52331, "count": 3}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.522945, "count": 1}, {"text": "relevant security Product description", "sentiment": {"score": -0.393941, "mixed": "1", "label": "negative"}, "relevance": 0.522532, "count": 2}]}, "extracted_metadata": {"sha1": "40ee3ff2dc723c0b4989a57a08e37b003fcf97a6", "filename": "1543275289158.zip-78047b053005173515481b0bdd7d3324.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "forum_title": "All News | Business Wire"}, {"id": "STIqMn94-IcLHxTGFlxZG_28lRi-EZ9mHIpl4-foK6edw8bRzORtLa2msWPIzpl8", "result_metadata": {"score": 32.232418}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.858051, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.649159, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975763, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763569, "count": 1}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619358, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602167, "count": 1}]}, "crawl_date": "2018-11-26T23:27:21Z", "url": "https://www.businesswire.com/news/home/20181126005393/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T12:41:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.715752, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.684192, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.5683, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.381244, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.56007, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.543607, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.5425, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.514299, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.476931, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.468668, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453123, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,331,900 1.30%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,327,331 1.44%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,806,416 1.49%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,109,394 1.52%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,894 4.20%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,655,347 4.25%", "relevance": 0.453123, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453123, "type": "Quantity"}], "sentiment": {"document": {"score": 0.648726, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,655,347 4.25% 33,382,894 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,382,894 4.20"}, {"type": "Quantity", "text": "33,655,347 4.25"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,327,331 1.44% 12,109,394 1.52% (2) Cash-settled derivatives: 11,806,416 1.49% 10,331,900 1.30% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,655,347 4.25% 33,382,894 4.20% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,655,347 4.25% 33,382,894 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,382,894 4.20"}, {"type": "Quantity", "text": "33,655,347 4.25"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,327,331 1.44% 12,109,394 1.52% (2) Cash-settled derivatives: 11,806,416 1.49% 10,331,900 1.30% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,655,347 4.25% 33,382,894 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 26 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659968 Time of Receipt (offset from UTC): 20181126T122847+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.953583, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.758153, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.694434, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.603045, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.515739, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.429018, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.388893, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.377857, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.374714, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "United States dollar", "relevance": 0.360586, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Security", "relevance": 0.35185, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Bond", "relevance": 0.325153, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}], "categories": [{"score": 0.858386, "label": "/real estate/buying and selling homes"}, {"score": 0.791513, "label": "/finance/financial news"}, {"score": 0.786377, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 600 4,394.0000 JPY Ordinary NPV CFD Long 24,500 4,366.5633 JPY Ordinary NPV SWAP Short 44 4,357.8448 JPY Ordinary NPV SWAP Short 104 4,361.5032 JPY Ordinary NPV SWAP Short 107 4,358.7956 JPY Ordinary NPV SWAP Short 228 4,361.6378 JPY Ordinary NPV SWAP Short 558 4,359.5644 JPY Ordinary NPV SWAP Short 683 4,361.1055 JPY Ordinary NPV SWAP Short 1,194 4,357.6457 JPY Ordinary NPV SWAP Short 1,841 4,356.3033 JPY Ordinary NPV SWAP Short 4,516 4,360.0644 JPY Ordinary NPV SWAP Short 15,700 4,357.0983 JPY Ordinary NPV SWAP Short 27,725 4,359.6598 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [6679, 6680], "entities": [{"type": "Person", "text": "JPY Ordinary NPV CFD"}]}, {"text": "Writing", "location": [6682, 6689], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7653, 7659], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7670, 7677], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 26 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8579, 8585], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8593, 8597], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [9025, 9031], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [9039, 9052], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8660, 8684], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8652, 8657], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [11245, 11269], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [11237, 11242], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8819, 8824], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8838, 8865], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [11404, 11409], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [11423, 11450], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [9101, 9107], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [9133, 9145], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [10739, 10740], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [10730, 10738], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659968 Time of Receipt (offset from UTC): 20181126T122847+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [11550, 11553], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [11529, 11536], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.743884, "count": 1}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.665443, "count": 15}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.64058, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.639442, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.626063, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.64284, "label": "positive"}, "relevance": 0.613843, "count": 4}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.612273, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.592987, "count": 1}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.57784, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.575043, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.574016, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.580831, "label": "positive"}, "relevance": 0.571696, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570939, "count": 1}, {"text": "options", "sentiment": {"score": 0.771929, "label": "positive"}, "relevance": 0.569615, "count": 4}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.568571, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.560357, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555166, "count": 1}, {"text": "Code", "sentiment": {"score": -0.304226, "mixed": "1", "label": "negative"}, "relevance": 0.55246, "count": 5}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.550337, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.547441, "count": 3}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.541641, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.538618, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.53846, "label": "positive"}, "relevance": 0.53853, "count": 2}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538501, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.534506, "count": 2}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.533888, "count": 9}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.531593, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.531593, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.530792, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530528, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.530409, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.529728, "count": 1}, {"text": "positions", "sentiment": {"score": 0.806498, "label": "positive"}, "relevance": 0.529378, "count": 2}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.529044, "count": 5}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528605, "count": 1}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52762, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525774, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524492, "count": 1}, {"text": "Sales", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.524161, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523424, "count": 1}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.52334, "count": 4}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.523339, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.42085, "label": "positive"}, "relevance": 0.523339, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.523024, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.52302, "count": 2}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.522819, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.522607, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52244, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522123, "count": 1}, {"text": "JPY Ordinary NPV SWAP Short", "sentiment": {"score": 0.969505, "label": "positive"}, "relevance": 0.520246, "count": 11}]}, "extracted_metadata": {"sha1": "5069cdc3066d1e9d8e98a957d5a4b2ae456d0ec2", "filename": "1543274841976.zip-e2ca507c8c02997c2b24ce8fd90643e2.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "forum_title": "All News | Business Wire"}]}